Neurocrine Biosciences to Present at Upcoming Investor Conferences in March

Company Overview - Neurocrine Biosciences is a leading biopharmaceutical company focused on neuroscience, dedicated to developing treatments for neurological, neuroendocrine, and neuropsychiatric disorders [3] - The company has a diverse portfolio that includes FDA-approved treatments for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis, and uterine fibroids, as well as a robust pipeline of compounds in mid- to late-phase clinical development [3] Upcoming Events - Neurocrine Biosciences will participate in two investor conferences in March 2025: the TD Cowen 45th Annual Health Care Conference on March 4 at 11:10 AM Eastern Time in Boston, and the Leerink Global Healthcare Conference on March 11 at 11:20 AM Eastern Time in Miami [5] - Live webcasts of these presentations will be available on the company's website, with replays accessible approximately one hour after the events and archived for about one month [2]